Fungiscope – A Global Database for Rare Fungal Infec ons M. J. Vehreschild1, A. Hamprecht2, G. Fischer3, S. de Hoog4, J. J. Vehreschild5 and O.A. Cornely1,6 on behalf of The Fungiscope ECMM/ISHAM Working Group
11st Department of Internal Medicine, University of Cologne, Cologne, Germany, 2Institute for Medical Microbiology, Immunology and Hygiene, University of Cologne, Cologne, Germany, 3 Health Authorities of the State of Baden-Württemberg, Stuttgart, Germany, 4CBS Fungal Biodiversity Centre, Institute of the Royal Netherlands Academy of Arts and Sciences (KNAW), Utrecht, the Netherlands, P-808 51st Department of Internal Medicine, University of Cologne, Cologne, Germany, 6 Clinical Trials Centre Cologne, ZKS Köln, BMBF 01KN1106, University of Cologne, Cologne, Germany
www.fungiscope.net Abstract (Updated Version) Background Registra on for ClinicalSurveys.net
Background: • Worldwide increase in the incidence of We are coordina ng a global registry rare IFD for cases of rare invasive fungal • Limited clinical data on risk factors, diseases (IFD). Our objec ve is to Web-based clinical course, diagnosis and treatment Diagnos cs Search Engine broaden the knowledge on response Documenta on • Crea on of a global network is warranted epidemiology, to determine the clinical pa ern of disease, to describe and improve diagnos c Pa ents and Methods procedures and therapeu c Therapeu c Drug Culture/Biopsy Banking regimens, as well as to facilitate Monitoring Sta s cal Analysis exchange of clinical isolates among • University-based case registry • Collec on of demographic, clinical and the contributors. Figure 1: Project structure Figure 2: Pathogen distribu on, n=268 microbiological data on rare IFD
• Web-based electronic case report form Methods: at www.fungiscope.net Fungiscope™ - A Global Rare Fungal • Inclusion criteria: Cultural, Infec on Registry uses a web-based histopathological, an gen, or molecular electronic case form accessible via biologic evidence of IFD www.fungiscope.net. For inclusion in • Exclusion criteria: Infec ons due to the registry we require posi ve Aspergillus spp., Candida spp., cultures or histopathological, an gen Cryptococcus neoformans, Pneumocys s or molecular gene c evidence of IFD jiroveci and any endemic fungal infec on or coloniza on and the associated clinical symptoms • Case compensa on: 100 € for each and signs of invasive infec on. The evaluable case, 50 € for each isolate data entered onto the registry • Authorship policy: Restricted to those include demographics, underlying centers contribu ng pa ents or condi ons, neutrophil count, transla onal work to the subset concomitant immunosuppressive published medica ons, clinical signs and • Figure 1 shows an overview of the symptoms of IFD, site of infec on, project’s structure diagnos c tests performed, pathogen iden fica on, an fungal Results treatment, surgical procedures performed, response to treatment, • 268 pa ents with a rare invasive IFD overall survival and a ributable Figure 3: Risk factors of four most frequent pathogens registered between ‘06 - ’12 mortality. • 170 (63%) male pa ents
• Age range: <1-90 years (median: 45 Results: years) Overall, 268 cases have been • Pathogen distribu on shown in fig. 2 completed. Zygomycetes (n=100; • Distribu on of contribu ng centers: 37%), Fusarium spp. (n=46; 17%), Germany 66 cases, India 66 cases, Czech yeasts (n=40; 15%), and Republic 34 cases, Brazil 18 cases, Dema aceae (n=32; 12%) were the France 17 cases, Italy 17 cases, , Canada most frequently registered 15 cases, Austria 14 cases, Belgium, Croa a, Cuba, Denmark, France, Israel, pathogens. Chemotherapy or the Netherlands, Romania, Slovakia, allogeneic stem cell transplanta on Thailand, Turkey, USA <5 cases each for a haematological malignancy was • Prevalent risk factors (>=10%) of four the most predominant risk factor most frequent pathogens shown in fig. 3 (n=125; 47%), as well as diabetes • Prevalent sites of infec on (>=10%) of mellitus (n=64; 24%), stay at an ICU four most frequent pathogens shown in (n=48; 18%) and chronic renal fig. 4 disease (n=36; 13%). Sites of • Outcome and mortality four most infec on included the lung in 115 frequent pathogens shown in fig. 5 pa ents (43%), followed by blood stream infec ons (n=56; 21%), the Conclusions and Future Goals Figure 4: Sites of infec on for most frequent pathogens sino-nasal region (n=43, 16%) and deep so ssues (n=41; 15%). For • Increasing relevance of rare IFD 146 (54%) pa ents, a favourable • Efficient method: 268 cases of rare IFD outcome, defined as a complete or from Europe, North America, Asia and par al response to treatment of IFD South America documented. was documented. Overall mortality • 2011 goals: and mortality a ributable to IFD was - Comple on of sequencing of all isolates 43% (n=116) and 31% (n=82), - Introduc on of an epidemiological respec vely. survey - Improvement of the FungiQuest™ search Conclusion: engine - Publica on of another clinical The clinical relevance of rare IFD is subset analysis increasing steadily. In a short period Contact Details: of me, a wide variety of cases from Prof. Oliver A. Cornely, MD, FIDSA and Europe, Asia and South America Maria J.G.T. Vehreschild, MD could be documented. Further University Hospital of Cologne Figure 5: Outcome and mortality 1st Department of Internal Medicine inves gators are cordially invited to Kerpener Str. 62, 50937 Cologne, Germany contribute to Fungiscope. Tel.: +49 221 478 6494, Fax: +49 221 478 3611 Supported by unrestricted grants from Astellas Pharma, Gilead Sciences, MSD/Merck and Pfizer Pharma GmbH email: [email protected], [email protected]